Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies.

Biotechnology

Pharmaceutical

Infinity Pharmaceuticals

Eva Huang

Idelfonso Méndez

Devon Jones

Heywood Ellenburg

Mohammed Nurullah

Saveria Cristiano

Steve Cucinotta

Nora Zizlsperger

Somarajan Nair

Naglaa Fikry

Liya Megerssa

Jasim Uddin

Khaled Oukasha

Joseph McPherson

Deirdre Casale

Project and Operations Management

Scientific and Clinical Advisory Team

Healthcare Team

Science and Technology

Teams at Infinity Pharmaceuticals

Project and Operations Management

Scientific and Clinical Advisory Team

Healthcare Team

Science and Technology